Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal clues to slowed movement in Alzheimer's

NCT ID NCT02811653

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why people with Alzheimer's disease may move more slowly. Researchers will use brain MRI scans and simple reaction time tests in 155 participants with mild cognitive impairment or early dementia. The goal is to link brain lesions to attention-related motor slowing, which is not well understood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand attention problems in Alzheimer's by linking them to specific brain changes.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve patient health. Results may not apply to all Alzheimer's cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 155 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2015

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients * Age between 40 and 85 * French mother tongue * Consulting at the Amiens Memory Resource and Research Centre (CMRR) for: * MCI, according to Albert et al.'s criteria (Albert et al., 2011) * Mild dementia (MMSE\>20) due to AD, according to McKhann's criteria (McKhann et al., 2011). * Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005). * Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011). * Social security coverage * Healthy controls * Healthy age and gender matched volunteers will be recruited into the study from the general population. Exclusion Criteria: * Reading or writing difficulties related to a learning disorder or illiteracy. * A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure): * NYHA stage IV dyspnoea. * respiratory impairment requiring oxygen therapy. * liver impairment. * kidney failure, progressing neoplastic disease, or past or present alcohol abuse. * Past or present neurological disorders other than those having prompted consultation in the Memory Clinic: * stroke. * meningitis or encephalitis. * severe head injury. * sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments). * epilepsy (requiring ongoing treatment), * psychiatric disorders (other than treated depression). * treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state. * Impossibility to perform a neuropsychological evaluation or brain MRI. * Withdrawal from the study at any time, if desired. * Pregnancy * Contra-indication to MRI: * nerve stimulators * cochlear implants * ferromagnetic foreign bodies close to nervous structures in the eye or brain * cerebral shunts * dental appliances * Legal guardianship or incarceration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens

    RECRUITING

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.